anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
In some embodiments, a management system is configured to dynamically generate and/or adjust a step-by-step care regimen. The care regimen, or step-by-step plan, is broken down by the system into specific actions presented to a patient at specific times with tailored guidance on how to achieve the best effect of each step. The system can be configured to build tailored care plans that span contemplation phases, preparation phases, recovery phases, and long term care phases. In further embodiments, over the treatment life cycle, the system facilitates patient care compliance, planning and education, among other options. In other embodiments, the system is configured to dynamically capture and develop implicit relationship information on a patient's care journey, and augment care options for respective patients responsive to identifying implicit connections developed within the context of the patient's care journey (e.g., specified by patient provider, procedure, physician, comorbidities, etc.).
BACKGROUND: It is well known that kidney injury is vital organ damage in Fabry disease (FD). Renin-angiotensin system (RAS) inhibitors are known to reduce proteinuria in patients with chronic kidney disease (CKD) by dilating the glomerular export arteries and reducing intraglomerular pressure. This improvement in intraglomerular pressure, although lowering the glomerular filtration rate, is thought to prevent renal damage and be renoprotective in the long term. RAS inhibitors may be effective in FD patients with proteinuria to prevent the progression of kidney disease, however, the degree to which they are used in clinical practice is unknown.
METHODS: The J-CKD-DB-Ex is a comprehensive multicenter database that automatically extracts medical data on CKD patients. J-CKD-DB-Ex contains data on 187,398 patients in five medical centers. FD patients were identified by ICD-10. Clinical data and prescriptions of FD patients between January 1 of 2014, and December 31 of 2020 were used for the analysis.
RESULTS: We identified 39 patients with FD from the J-CKD-DB-Ex including those with suspected FD. We confirmed 22 patients as FD. Half of the patients received RAS inhibitors. RAS inhibitors tended to be used in CKD patients with more severe renal impairment.
CONCLUSIONS: This case series revealed the actual clinical practice of FD patients with CKD. In particular, we found cases in which patients had proteinuria, but were not treated with RAS inhibitors. The database was shown to be useful in assessing the clinical patterns of patients with rare diseases.
The present invention discloses an oral cavity instant preparation and a production method thereof, and supplementary materials of the oral cavity instant preparation contain pullulan. The oral cavity instant preparation comprises a substrate and an effective dose of main drug, wherein the substrate is mainly composed of the following raw materials: 1 to 10 wt% of skeleton supporter and 1 to 10 wt% of pullulan. The main drug can be a water soluble drug or a water insoluble drug. When the main drug is the water insoluble drug or a primary menstruum, a thickening and suspending agent can also be added to the substrate. The preparation method of the oral cavity instant preparation of the present invention comprises the steps of dissolution, degassing, injection molding, quick freezing, freeze drying, etc. In the preparation method, the step of ice crystal incubation can also be added after the step of quick freezing. The oral cavity instant preparation of the present invention has the advantages of favorable formability, smooth and clean surface, easy demoulding, crack resistance and wider requirements for the range and the proportional relations of the skeleton supporter.
Generally, the present disclosure is directed to managing shared resources in a multi-modality medical system. A multi-modality medical system acquires, stores, processes, and displays data associated with a plurality of different medical modalities. Although different, independent modules within the medical system handle different modality workflows, such modules rely on common resources in the system. The method and systems described herein coordinate usage of the common resources, such as a display viewport, among the independent modality modules. For example, a token-based, locking scheme is utilized to exclusively assign a shared resource to a single modality component. This locking scheme prevents, for example, resource deadlocks from occurring during a patient procedure, thus enhancing patient safety. This scheme also ensures, for example, that one diagnostic step in a patient procedure is completed before a second diagnostic step is started, and that all workflow operations halt in the event of an error.
Catheter-directed thrombolysis will be performed in eligible patients with acute IF-DVT. A combined mechanical thrombectomy will be used to clear the iliac thrombi in experimental group. The immediate, mid- and long-term outcomes will be recorded. Quantitative data wiil be expressed as mean ± SD, and will be compared with independent-sample t-test or paired-sample t-test. Count data will be expressed as a ratio (or percentage), and the chi-square test or the fisher's exact test will be used for comparisons. A difference with P \< 0.05 will be considered statistically significant. All statistical analyses will be performed using IBM SPSS, version 22.0 (SPSS Inc., Chicago, IL, USA).
Naltrexone has been used to fight existing infections, afflictions, and substance abuse. Embodiments of the current invention provide naltrexone as a preventative medicine taken daily, usually in the late evening for greater efficacy. It is taken in a low dose like a vitamin supplement and may prevent many diseases by stimulating the immune system. The increased endorphin levels resulting from the use of low dose naltrexone may also reduce the need for pain relief medications, plus counter tendencies toward experiencing undesirable moods, such as depression or anger. Increased feelings of well-being produced by naltrexone may also have far-reaching effects, as suggested by studies showing that people with positive attitudes recover more quickly from serious illnesses, for example. In another aspect of the invention, naltrexone may be used to prevent substance addiction before it ever starts, by blocking the internal positive response that normally results from the use of chemical substances.
This is an open-label (both \[participants and investigator\] know what treatment participants will receive) and multicenter study. The study is divided into 2 parts: Part 1: pharmacokinetics portion (Week 0 to Week 14); Part 2: study extension (Week 14 to Week 114). The focus of this study is to evaluate the pharmacokinetics and safety of golimumab. Additionally the efficacy of short-term therapy with golimumab will be evaluated. Participants in clinical response at Week 6 will continue to receive open label golimumab maintenance therapy and will enter the study extension at Week 14. Participants who are not in clinical response at Week 6 will be withdrawn from further treatment with golimumab. At Week 114, participants who, in the opinion of the investigator, may benefit from continued treatment will be eligible to continue to receive golimumab every 4 weeks until marketing authorization is obtained in the treatment of pediatric UC in that country, or until a decision has been made not to pursue an indication in pediatric UC. Approximately 30 participants will be enrolled in this study. The total duration of study participation for a participant will be approximately 126 weeks or longer.
Placebo tablets at 45 mg/day will be given for 10 days, after 10 days, the tablets will be reduced to 30 mg/day. The treatment will be continued for 4 weeks (28 days) total.
Participants will keep headache diaries for 4 weeks, followed by baseline assessments + 8 weeks of daily headache monitoring (as a parallel to the PainCOACH intervention). Post-assessments will immediately follow, and participants later will complete follow-up assessments at 3 and 6 months.
The invention discloses a rose extract capable of improving the organism immunity and applications thereof. The rose extract comprises rose flower essential oil and distilled juice of rose flower. The rose species comprise rosa rugosa, rosa damascena, and double-petal red rose. The invention also relates to the applications of the provided rose extract. The rose extract can be added into beverages to produce a rose juice beverage, or can be added into a chemical matrix to prepare creams and emulsion. The functional components of the rose extract are reasonably compounded according to the different characteristics of fragrances so as to achieve an optimal effect, and the active components, nutrients, and fragrances cooperate with each other to generate a synergetic effect so as to improve the activity of immunity system. The extract can be added to beverages or cosmetics, the content of the rose extract is high, and the rose extract can prominently promote and maintain the healthy state of organism.
PROBLEM TO BE SOLVED: To obtain a preparation for external use for skin good in usability and stability, and excellent in moisturizing effect, containing a water-soluble polymer and a specific compound derived from escin, an extract of the seeds of Aesculus hippocastanum. SOLUTION: This preparation for external use for skin contains a water-soluble polymer and an escinol (salt) of the formula (R<1> is H or OH; R<2> is a pyranose residue). The escinol is obtained by alkalinolysis of escin in the extract of the seeds of Aesculus hippocastanum to effect elimination of the acyl group. The content of the escinol (salt) in the whole amount of the preparation is pref. 0.001-20 (esp. 0.1-7)wt.%. The water-soluble polymer is e.g. gum arabic, xanthan gum, collagen, carbomethyl starch, methyl cellulose, polyvinyl alcohol, its content in the whole amount of the preparation being pref. 0.01-5 (esp. 0.1-1)wt.%.
The stem cell field is hindered by the inability to noninvasively monitor transplanted cells within a target organ in a repeatable, time sensitive, and condition specific manner. It was hypothesized that the quantitation and intraexosomal cargo characterization of circulating transplanted cell specific exosomes would enable a reliable, noninvasive surveillance platform to reflect the conditional activity of their cellular counterparts. To test this hypothesis, use was made of a human-into-rat-xenogeneic myocardial infarction model involving two well-studied progenitor cell types: cardiosphere-derived cells (CDCs) and c-kit+cardiac progenitor cells (CPCs), derived from the same right atrial appendage of adult humans. To noninvasively monitor the activity of transplanted CDCs or CPCs in vivo, recipient plasma exosomes were purified using antibodies to human leukocyte antigen (HLA) surface molecules only expressed on human exosome surface. After 7 days post-transplantation, a 2.5 fold increase in concentration of plasma CPC-specific exosomes was observed when compared to CDC-specific exosomes. Computational pathway analysis failed to link CPC or CDC cellular mRNA with observed myocardial recovery. However, myocardial recovery was strongly linked to the miRNA cargo of CPC exosomes purified from recipient plasma. In addition, mechanistic pathways governing myocardial recovery were identified to specific outcomes by the transplanted CPCs. Collectively, these findings demonstrate the potential of circulating progenitor cell specific- exosomes as a liquid biopsy that provides a noninvasive window into the conditional state of the transplanted cells.
A wipe warmer having a container to receive liquid and sponge pad therein, where the container is placed under the wipes to keep the wipes moist. The container has a top and a support plate within, both of which are perforated allowing moisture to pass through. These perforations offset each other to facilitate efficient saturation of the sponge pad, when the sponge pad is placed between the perforated top and the perforated plate. Further, the container can be a removable basket-like structure. Alternatively, all or part of the container can be an integral part of the wipe warmer. While the wipes can be placed on top of the container, an alternative design is to place the wipes and the container side-by-side.
BACKGROUND: Reducing the prevalence of hospital-acquired complications (HACs) is paramount for both patient safety and hospital financial performance because of its impact on patient's recovery and health service delivery by diverting resources away from other core patient care activities. While numerous reports are available in the literature for projects that successfully reduce specific HAC, questions remain about the sustainability of this isolated approach and there may be benefits for more wholistic programmes that aim to align prevention strategies across a hospital. This study describes such a programme that uses evidence and theories in the literature to achieve and sustain a reduction in HACs in an Australian local health service between 2019 and 2022.
METHODS: An organisation-wide HACs Reduction Programme underpinned by a 3-pillar strategic framework (complete documentation, accurate coding, clinical effectiveness) and a 5-year roadmap to clinical excellence was developed. Priorities were identified through Pareto analysis and aligned at organisational, service and specialty levels. The Institute for Healthcare Improvement (IHI) 90-day cycle was modified to implement contextualised evidence-based interventions supported by the application of the Awareness, Desire, Knowledge, Ability and Reinforcement change management model. Under this wholistic umbrella, specific projects were data-driven, evidence-based and outcome-oriented to promote clinical engagement and a continuous improvement culture.
RESULTS: Overall mean HAC rate per 10 000 episodes of care decreased from a baseline of 459.5 across 2017 and 2018 to 363.1 in 2019 and remained lower through to the end of 2022 indicating sustained improvement in performance.
CONCLUSION: A wholistic approach to reduce HACs increased the likelihood of multidisciplinary integration for contextualised strategies and interventions. Improvement work, particularly in relation to patient outcomes, is a dynamic process that needs to be intentionally cultivated, targeted and coordinated. The modified IHI 90-day cycle proved to be an effective tool for implementation that contributed to sustained change.
Chemotherapy with doxorubicin (Dox) can lead to cardiotoxic effects, presenting a major complication in cancer therapy. Diindolylmethane (DIM), derived from cruciferous vegetables like cabbage, exhibits numerous health benefits. However, its clinical application is limited because of low bioavailability and suboptimal natural concentrations in dietary sources. To address this limitation, we developed a processing methodology, specifically fermentation and boiling, to enhance DIM levels in cabbage. High-performance liquid chromatography (HPLC) analysis revealed a threefold DIM increase in fermented cabbage and a substantial ninefold increase in fermented-boiled cabbage compared to raw cabbage. To evaluate the clinical implications, we formulated a DIM-enriched diet and administered it to mice undergoing Dox treatment. Our in vivo results revealed that Dox treatment led to cardiotoxicity, manifested by changes in body and heart weight, increased mortality, and severe myocardial tissue degeneration. Dietary administration of the DIM-enriched diet enhanced antioxidant defenses and inhibited apoptosis in the cardiac tissue by interfering with mitoptosis and increasing antioxidant enzyme expression. Interestingly, we found that the DIM-enriched diet inhibited the nuclear translocation of NF-kB in cardiac tissue, thereby downregulating the expression of inflammatory mediators such as TNF-α and IL-6. Further, the DIM-enriched diet significantly reduced serum cardiac injury markers elevated by Dox treatment. These results suggest that the DIM-enriched cabbage diet can serve as a complementary dietary intervention for cancer patients undergoing chemotherapy. Further, our research highlights the role of plant-based diets in reducing treatment side effects and improving the quality of life for cancer patients.
NEW MATERIAL:1-Methyl-4,5-dihydroorotyl-histidyl-proline amide expressed by formula I or an acid addition salt thereof. USE:A remedy for central nervous diseases, especially exhibiting a more powerful antagonism to a pentobarbital anesthesia than a thyrotropin-releasing-hormone (TRH), etc. and having little side effect and high safety. PREPARATION:A compound expressed by formula II (X<1> is an optionally protected imino group) or a reactive thereof is condensed with a compound expressed by formula III (X<2> is an optionally protected imino group) or a salt thereof in a solvent such as tetrahydrofuran (THF), in some cases in the presence of a deacidifying agent (example; alkali metal hydroxide, etc.), preferably at -10-10 deg.C. Thereafter the protecting group thereof is eliminated, and the resultant product is converted into its acid addition salt if desired.
Arterial stiffness is defined as stiffening of the arterial wall and refers to a decrease in the capacity of an artery to expand and contract in response to pressure changes in the vessel. The parameters indicating arterial stiffness are compliance and distensibility of the vessel.

Imbalance in the formation of vasodilator and vasoconstrictor signaling molecules acting on the vessel is an important determining factor in the development of endothelial dysfunction, which is often exacerbated by oxidative stress. Disruption of the balance between oxidants and antioxidants in favor of oxidants leads to disruption of the elastin-collagen ratio in the vessel wall in favor of collagen and ultimately to the development of arterial stiffness. Regular exercise is beneficial both to prevent the development of arterial stiffness and to reduce arterial stiffness. Although many mechanisms have been mentioned for exercise to improve endothelial function, there is no clear consensus on the mechanisms by which exercise increases arterial compliance, which is one of the indicators of atherosclerosis. While the beneficial impacts of physical activity on arterial stiffness are well-documented, this varies considerably among sports disciplines. For instance, there are studies showing that endurance training decreases arterial stiffness in young adults and elderly individuals, whereas strength training increases arterial stiffness. Arterial stiffness is lower in endurance athletes with a longer sports history and higher in those with a strength training history. The weekly training time of competitive young athletes is well beyond the amount of exercise required for healthy living. It has also been suggested that this excessive amount of time may trigger some unfavorable adaptations in the cardiovascular system. In addition, the number of studies examining the effects of regular exercise training at these levels on the vascular system is limited. Studies indicate that changes in arterial stiffness start at early ages and this is also true for young athletes who perform regular training in the infrastructures of various sports branches. Therefore, our aim is investigating the relationship between the oxidative stress parameters and aortic stiffness in adolescent male football players and comparing with the healthy control group. Secondly, the investigators will evaluate if there is any difference between the aortic stiffness and oxidative response to acute exercise training in adolescent male football players?
BACKGROUND: Breast cancer is the most common malignant tumor in females worldwide. During disease development, breast cancer patients suffer anxious and depressed, which may lead to worse quality of life or even higher mortality. Esketamine has been regarded as an antidepressant in breast cancer patients with mild or moderate depression. Here, we wonder whether the administration of esketamine could reduce the postoperative depressive symptom score of breast cancer patients who have no preoperative depression.
METHODS: A total of 64 patients treated with unilateral modified radical mastectomy were randomly divided into an experimental group (esketamine group, Group E) and a control group (Group C), with 32 cases in each one. After anesthesia induction, Group C received 0.2 ml/kg of normal saline intravenously and Group E was administered 0.2 mg/kg intravenous esketamine. The primary outcome was the Patient Health Questionnaire-9 (PHQ-9) scores. The secondary outcomes included the Visual Analogue Scale (VAS) scores for pain, inflammatory markers, perioperative-related indicators, and the incidence of postoperative delirium, nausea and vomiting.
RESULTS: The PHQ-9 score on postoperative day (POD) 1 in Group E declined from the preoperative level, while the score in Group C was higher than before, and the former was far lower than the latter (P = 0.047). There is no statistically significant difference in PHQ-9 scores between Group E and Group C on POD 3, 7, and 30. Moreover, the postoperative leukocyte level of Group E was higher than that of Group C, and the difference was statistically significant (P = 0.030).
CONCLUSIONS: A single subanesthetic dose of esketamine can result in lower postoperative score on subthreshold depressive symptoms compared to the Group C on POD 1, without increasing the occurrence of postoperative adverse reactions.
TRIAL REGISTRATION: Registration number: Chinese Clinical Trial Registry ChiCTR2200057028. Date of registration: 26/02/2022.
We present the first results of the proof-of-concept phase 2a study of oral NLRP3 inflammasome inhibitor in subjects with cryopyrin-associated periodic syndromes (CAPS). Three adult subjects with a confirmed diagnosis of CAPS were enrolled and administered 50 mg of ZYIL1 twice daily for 7 days. A total of 5 treatment-emergent adverse events (TEAEs) were reported in 2 subjects. All 5 TEAEs were mild in severity and considered unrelated to the study drug. At steady state, the average plasma concentration and trough concentration ranged from 2.5 to 4.2 and 1.4 to 2.5 µg/mL, respectively. Inflammatory markers and disease activity (physician and patient global assessment score) decreased notably 12 hours post-last dose.
The Doxycycline treated group will enroll 125 participants. 100 patients with Grades 1-3 lymphedema per study site (based on end point and duration) and up to 25 patients with grade 4-6 lymphedema/per study site. Each patient will receive Doxycycline hyclate 200 mg per day x 6 weeks for patients \>50 kg or 100 mg per day for patients \<50 kg).